STE · 10-Q · 2026Q3

STERIS plc

Filed 2026-11-05 · Healthcare · View original filing on EDGAR

Everything STE's SEC filings said, ranked

Ranked Events

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  On October 11, 2026, STERIS entered into an agreement to acquire Xodus Medical for approximately $2.1 billion in cash at closing, subject to customary adjustments, plus potential earnout consideration of up to $150.0…
• Capital Return ProgramImportance 69 · Surprise 64
  STERIS repurchased 0.9 million ordinary shares for $200.0 million through its share repurchase program in the first six months of fiscal 2027, compared with 0.4 million shares for $100.0 million in the prior-year…
• Geographic Market CommentaryImportance 54 · Surprise 40
  For the six months ended September 30, 2026, U.S. revenue increased 7.8% to $2,264.9 million, while revenue from other foreign locations increased 8.7% to $761.4 million. Growth in other foreign locations reflected…
• Segment ProfitabilityImportance 54 · Surprise 40
  For the six months ended September 30, 2026, operating income increased 7.0% to $529.4 million in Healthcare, 4.0% to $275.1 million in AST, and 16.0% to $137.5 million in Life Sciences. Healthcare’s six-month…
• Segment Revenue PerformanceImportance 54 · Surprise 40
  For the six months ended September 30, 2026, Healthcare revenue rose 8.1% to $2,170.8 million, AST revenue rose 5.4% to $593.2 million, and Life Sciences revenue rose 13.3% to $317.4 million. Healthcare growth…
• North Carolina Chemistry ConsolidationImportance 52 · Surprise 42
  The Fiscal 2027 Manufacturing Restructuring Plan will consolidate formulated-chemistry manufacturing and distribution at a new North Carolina Center of Excellence and close facilities in St. Louis, Missouri, and…
• Capital Expenditures and Free Cash FlowImportance 49 · Surprise 32
  For the first six months of fiscal 2027, operating cash flow was $656.1 million and free cash flow was $492.5 million, down from $707.8 million and $527.7 million, respectively, a year earlier. The decreases reflected…
• Revenue Performance and MixImportance 49 · Surprise 32
  For the six months ended September 30, 2026, revenue increased 8.1% to $3,081.3 million from $2,851.4 million, driven by higher volume in Healthcare and Life Sciences and higher pricing across all three segments.…
• Portfolio and Organizational OptimizationImportance 46 · Surprise 42
  During the second quarter of fiscal 2027, STERIS approved a targeted plan covering facility realignment, product rationalization, and organizational realignment. The company anticipates approximately $45 million in…
• Income Tax Rate ChangesImportance 40 · Surprise 30
  The effective income tax rate increased to 25.7% in the three months ended September 30, 2026, from 23.9% a year earlier, and to 26.1% for the six months from 23.6%. Six-month income tax expense rose 27.9% to $146.4…
• Liquidity and Debt PositionImportance 36 · Surprise 14
  Commercial commitments were approximately $160.3 million at September 30, 2026, down $1.0 million from March 31, 2026. STERIS had no outstanding borrowings under its Revolving Credit Facility and $5.3 million of…
• Operating Expense TrendsImportance 29 · Surprise 22
  For the six months ended September 30, 2026, SG&A increased 4.6% to $735.7 million, primarily from compensation and benefit costs, professional fees, and dealer commissions, partly offset by favorable foreign currency…
• Gross Margin DriversImportance 25 · Surprise 32
  Gross profit percentage for the second quarter of fiscal 2027 increased to 44.7% from 44.2%, while six-month gross profit percentage increased to 45.3% from 44.7%. In the quarter, pricing added 130 basis points, tariff…
• Products and TechnologyImportance 23 · Surprise 24
  STERIS’s fiscal 2027 R&D initiatives emphasize sterile processing technologies, procedural products and accessories, and devices and support accessories used in gastrointestinal endoscopy procedures. The company says…
• Market Demand TrendsImportance 10 · Surprise 6
  STERIS attributes demand across its healthcare, medical-device, and pharmaceutical markets to population aging, advances in healthcare delivery, and adoption of new technologies. Increased demand for medical…

Revenue by Product (in millions)

Revenue by Geography (in millions)